Researchers at Wonderfeel, led by Dr. Andrew Salzman, outline how nicotinamide mononucleotide (NMN) supplementation increases NAD availability, driving mitochondrial energy production and enhancing DNA repair mechanisms. Their analysis compares the efficacy of NMN versus NR precursors, highlights optimal dosing around 900 mg daily, and reviews the latest clinical data demonstrating benefits in energy metabolism, cognitive function, and metabolic health. The report also examines formulation quality factors like purity, stability, and third-party testing.

Key points

• NMN increases NAD+ via direct intracellular conversion, fueling mitochondrial ATP production.
• Clinical trials show 900 mg/day NMN improves endurance and cognitive metrics in adults.
• Formulations achieve ≥99% NMN purity with protective packaging against oxidation.
• NMN’s one-step conversion to NAD+ is more efficient than NR’s two-step pathway.
• Third-party GMP/ISO certification ensures supplement consistency, potency, and safety.

Why it matters: Boosting NAD+ levels through NMN supplementation represents a paradigm shift in preventative gerontology, offering a scalable, non-invasive approach to sustaining cellular energy and genomic stability. By leveraging clinically validated precursors and optimized formulations, this strategy may circumvent limitations of direct NAD delivery, furnishing impactful applications in metabolic, cognitive, and cardiovascular aging.